drugset / Trial / NCT02671955
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-01
- Completion
- 2017-07
Outcome
Outcome not reported
Stopped (Business): “Janssen business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ONVATILIMAB | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.